Received Apr 22, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | 99HE4 | IM |
patient received the first dose of SHINGRIX 29 DEC 2022 and the second dose of SHINGRIX 11 APR 2025; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 64-year-old female patient who received Herpes zoster (Shingrix) (batch number 99HE4, expiry date 29-MAR-2027) for prophylaxis. Previously administered products included Shingrix (received 1st dose on 29-DEC-2022). On 11-APR-2025, the patient received the 2nd dose of Shingrix (intramuscular) .5 ml. On 11-APR-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: patient received the first dose of SHINGRIX 29 DEC 2022 and the second dose of SHINGRIX 11 APR 2025). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK receipt date: 17-APR-2025 The pharmacist reported that the patient received 2nd dose of Shingrix, later than the recommended interval, which led to lengthening of vaccination schedule. The pharmacist reported that a first dose at Month 0 followed by a second dose administered 2 to 6 months later is recommended dose schedule as per PI.